Skip to content
Screener

Jazz Pharmaceuticals JAZZ Xywav — Number of patents, paragraph IV certification notice filed

Similar metrics at other companies

Where Food Comes From logo
WFCFVerification And Certification Service Revenue — Revenue
$5.39M+1.1%
Where Food Comes From logo
WFCFVerification And Certification Service Revenue — Cost Of Revenue
$3.2M-2.5%
Haemonetics logo
HAENumber of petitions filed
$9
Haemonetics logo
HAENumber of petitions filed
9
UL Solutions logo
ULSCertification Testing — Revenue
$211M+11.6%
UL Solutions logo
ULSOngoing Certification Services — Revenue
$265M+8.2%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$16.98B+165%
Enterprise value$21.71B+104%
P/S3.8×+2.3×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept jazz:NumberOfPatentsParagraphIVCertificationNoticeFiled.

The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001232524-26-000025

In January 2026, we received notices from Tris Pharma that it had filed with FDA a Section 505(b)(2) NDA with Xyrem and Xywav as reference listed drugs. The first notice included a paragraph IV certification with respect to seven patents listed in FDA’s Orange Book for Xyrem, and the second notice included a paragraph IV certification with respect to fifteen patents listed in FDA’s Orange Book for Xywav on the date of our receipt of the notice. Seven of the listed patents relate generally to methods of treatment when Xywav or Xyrem is administered concomitantly with certain other medications, and the remaining eight relate generally to the composition and method of use of Xywav.

Item 1.Financial Statements

FAQ

What is Jazz Pharmaceuticals's xywav — number of patents, paragraph IV certification notice filed?
Jazz Pharmaceuticals (JAZZ) reported xywav — number of patents, paragraph IV certification notice filed of 15 in Q1 2026.
What does xywav — number of patents, paragraph IV certification notice filed mean?
This metric tracks the count of Paragraph IV certification notices received from generic drug manufacturers challenging the validity or enforceability of patents protecting a specific pharmaceutical product. It serves as a critical indicator of potential future generic competition and the strength of the company's intellectual property moat. Monitoring this helps investors assess the timing and risk of market exclusivity erosion for key revenue-generating assets.

Ask your AI about Jazz Pharmaceuticals's xywav — number of patents, paragraph iv certification notice filed.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude